About: Severe pneumococcal pneumonia: impact of new quinolones on prognosis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Severe pneumococcal pneumonia: impact of new quinolones on prognosis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Severe pneumococcal pneumonia: impact of new quinolones on prognosis
Creator	Alfandari, Serge Boussekey, Nicolas Chiche, Arnaud Devos, Patrick Georges, Hugues Leroy, Olivier Meybeck, Agnes Olive, David
Source	PMC
abstract	BACKGROUND: Most guidelines have been proposing, for more than 15 years, a β-lactam combined with either a quinolone or a macrolide as empirical, first-line therapy of severe community acquired pneumonia (CAP) requiring ICU admission. Our goal was to evaluate the outcome of patients with severe CAP, focusing on the impact of new rather than old fluoroquinolones combined with β-lactam in the empirical antimicrobial treatments. METHODS: Retrospective study of consecutive patients admitted in a 16-bed general intensive care unit (ICU), between January 1996 and January 2009, for severe (Pneumonia Severity Index > or = 4) community-acquired pneumonia due to non penicillin-resistant Streptococcus pneumoniae and treated with a β-lactam combined with a fluoroquinolone. RESULTS: We included 70 patients of whom 38 received a β-lactam combined with ofloxacin or ciprofloxacin and 32 combined with levofloxacin. Twenty six patients (37.1%) died in the ICU. Three independent factors associated with decreased survival in ICU were identified: septic shock on ICU admission (AOR = 10.6; 95% CI 2.87-39.3; p = 0.0004), age > 70 yrs. (AOR = 4.88; 95% CI 1.41-16.9; p = 0.01) and initial treatment with a β-lactam combined with ofloxacin or ciprofloxacin (AOR = 4.1; 95% CI 1.13-15.13; p = 0.03). CONCLUSION: Our results suggest that, when combined to a β-lactam, levofloxacin is associated with lower mortality than ofloxacin or ciprofloxacin in severe pneumococcal community-acquired pneumonia.
has issue date	2011-03-15(xsd:dateTime)
bibo:doi	10.1186/1471-2334-11-66
bibo:pmid	21406091
has license	cc-by
sha1sum (hex)	463d44f3bcccc8432f468012eb3f708a8828a327
schema:url	https://doi.org/10.1186/1471-2334-11-66
resource representing a document's title	Severe pneumococcal pneumonia: impact of new quinolones on prognosis
has PubMed Central identifier	PMC3065411
has PubMed identifier	21406091
schema:publication	BMC Infect Dis
resource representing a document's body	covid:463d44f3bcccc8432f468012eb3f708a8828a327#body_text
is schema:about of	named entity 'patients' named entity 'levofloxacin' named entity 'antimicrobial' named entity 'combined' named entity 'Streptococcus' named entity 'Pneumonia' named entity 'treated' named entity 'received' named entity 'pneumococcal pneumonia' named entity 'BMC' named entity 'ADMISSION' named entity 'STREPTOCOCCUS PNEUMONIAE' named entity 'OUR' named entity 'PATIENTS' named entity 'RESULTS' named entity 'OLD' named entity 'BED' named entity 'OFLOXACIN' named entity 'ASSOCIATED WITH' named entity 'NEW' named entity 'RATHER' named entity '95% CI' named entity 'severe' named entity 'severe' named entity 'identified' named entity 'combined' named entity 'AOR' named entity 'bed' named entity 'combined' named entity 'β-lactam' named entity 'first-line therapy' named entity 'severe' named entity 'ICU' named entity 'quinolones' named entity 'ofloxacin' named entity 'β-lactam' named entity 'ciprofloxacin' named entity 'macrolide' named entity '0.01' named entity 'penicillin-resistant' named entity 'ofloxacin' named entity 'ICU' named entity 'intensive care unit' named entity 'Retrospective study' named entity 'ofloxacin' named entity 'mechanical ventilation' named entity 'regression analysis' named entity 'Organ Failure' named entity 'IDSA' named entity 'β-lactams' named entity 'hospital-acquired' named entity 'quinolones' named entity 'CAP' named entity 'prognosis' named entity 'S.pneumoniae' named entity 'intensive insulin therapy' named entity 'antibiotics' named entity 'ICU' named entity 'retrospective studies' named entity 'beta-lactam' named entity 'ciprofloxacin' named entity 'CAP' named entity 'moxifloxacin' named entity 'S. aureus' named entity '1.000' named entity 'radiographic' named entity 'LRT' named entity 'mm Hg' named entity 'causative agent' named entity 'Physiology' named entity 'Streptococcus spp' named entity 'antibiotic' named entity 'intensive insulin therapy' named entity 'fluoroquinolone'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software